Jazz Disputes FDA’s Approval Of Lumryz Over Xywav’s Orphan Exclusivity, Citing Lack Of Comparative Study

 
• By Brenda Sandburg
Narcolepsy
Jazz Pharmaceuticals sues FDA over its approval of a competing narcolepsy drug • Source: Shutterstock

More from Legal & IP

More from Pink Sheet